What it is
Mazdutide (IBI362) is an investigational dual GLP-1 / glucagon receptor agonist studied for obesity and type-2 diabetes.
Evidence boundary
Human evidence exists, but it is still investigational.
Trial evidence
- PMID 42410325 — Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- PMID 41804840 — Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
- PMID 39968298 — Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
- PMID 39305981 — Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–4 | 2.5 mg | 50 U (0.5 mL) | Once weekly | 2.5 mg/week |
| Weeks 5–8+ | 5 mg | 100 U (1 mL) | Once weekly | 5 mg/week |
Weeks 1–4
- Dose
- 2.5 mg
- Draw / measure
- 50 U (0.5 mL)
- Frequency
- Once weekly
- Weekly total
- 2.5 mg/week
Weeks 5–8+
- Dose
- 5 mg
- Draw / measure
- 100 U (1 mL)
- Frequency
- Once weekly
- Weekly total
- 5 mg/week
Weekly totals apply only during the active phase.
Titration rules
- 2.5 mg weekly is the cautious start.
- 5 mg weekly is the main collected maintenance step.
- Keep the schedule simple unless source material says otherwise.
Cycle length and breaks
Use only the defined schedule window and reassess before extending it.
What to monitor
- Weight-loss response
- HbA1c / glycemic response
- Blood pressure and liver-fat signals where studied
- GI effects during escalation
- Tolerability
- Do not read this as an approved product.
Practical rules
- Subcutaneous, once weekly.
- Rotate injection sites.
- Use smaller meals and slower titration if GI effects show up.
- Keep protein and resistance training in the plan if lean mass matters.